Clinical Trial Update: Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on AXA1125 for nonalcoholic steatohepatitis (NASH) with fibrosis focusing on safety, tolerability, and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non Alcoholic Steatohepatitis

Drugs mentioned

• AXA1125 (AXA1125)

Snippet

Sponsor: Axcella Health, Inc | Conditions: Non Alcoholic Steatohepatitis (NASH) | Phase 2 | Status: UNKNOWN